An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function  by Holtkamp, Frank A. et al.
see commentary on page 235
An acute fall in estimated glomerular filtration rate
during treatment with losartan predicts a slower
decrease in long-term renal function
Frank A. Holtkamp1, Dick de Zeeuw1, Merlin C. Thomas2, Mark E. Cooper2, Pieter A. de Graeff1, Hans J.L.
Hillege3, Hans-Henrik Parving4, Barry M. Brenner5, Shahnaz Shahinfar6 and Hiddo J. Lambers Heerspink1
1Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
2Diabetes & Metabolism Division, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia; 3Department of
Cardiology/Epidemiology, University Medical Center Groningen, University of Groningen, The Netherlands; 4Department of Medical
Endocrinology, University Hospital of Copenhagen, Copenhagen, Denmark; 5Renal Division, Department of Medicine, Brigham and
Women’s Hospital, and Harvard School of Medicine, Boston, Massachusetts, USA and 6Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania, USA
Intervention in the renin-angiotensin-aldosterone-system
(RAAS) is associated with slowing the progressive loss of
renal function. During initiation of therapy, however, there
may be an acute fall in glomerular filtration rate (GFR).
We tested whether this initial fall in GFR reflects a renal
hemodynamic effect and whether this might result in a
slower decline in long-term renal function. We performed
a post hoc analysis of the Reduction of Endpoints in
Non-Insulin-Dependent Diabetes Mellitus with the
Angiotensin II Antagonist Losartan (RENAAL) trial. Patients
assigned to losartan had a significantly greater acute fall in
estimated (eGFR) during the first 3 months compared to
patients assigned to placebo, but a significantly slower long-
term mean decline of eGFR thereafter. A large interindividual
difference, however, was noticed in the acute eGFR change.
When patients were divided into tertiles of initial fall in eGFR,
the long-term eGFR slope calculated from baseline was
significantly higher in patients with an initial fall compared to
those with an initial rise. When eGFR decline was calculated
from 3 months to the final visit, excluding the initial effect,
patients with a large initial fall in eGFR had a significant lower
long-term eGFR slope compared to those with a moderate
fall or rise. This relationship was independent of other risk
markers or change in risk markers for progression of renal
disease such as blood pressure and albuminuria. Thus, the
greater the acute fall in eGFR, during losartan treatment, the
slower the rate of long-term eGFR decline. Hence,
interpretation of trial results relying on slope-based GFR
outcomes should separate the initial drug-induced GFR
change from the subsequent long-term effect on GFR.
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Diabetic nephropathy is the most common cause of end-stage
kidney disease (ESRD). Agents that block the renin-angiotensin-
aldosterone-system (RAAS) can prevent the onset and progres-
sion of nephropathy, attenuate deterioration of kidney function,
and improve survival in patients with diabetes.1–4
Data from small-scale studies have suggested that treatment
with blood pressure-lowering medication, including angioten-
sin-converting enzyme (ACE) inhibitors or angiotensin-II
receptor blockers (ARBs), is associated with an initial fall in
glomerular filtration rate (GFR) or increase in serum
creatinine levels, most likely resulting from a reduction in
intraglomerular pressure.5–7 In daily practice, a rise in serum
creatinine may inappropriately raise safety concerns that
prevent clinicians from using sufficiently high doses of ACE
inhibitors or ARBs or from continuing treatment altogether. A
systematic review showed that a rise in serum creatinine of up
to 30% of baseline levels is no reason for concern, provided
serum electrolytes (principally potassium) remain within
normal limits.8 A small-scale study in patients with chronic
kidney disease even indicates that the magnitude of initial fall
in GFR is inversely related to the long-term slope of GFR
decline and is reversible after termination of RAAS blockade.9
These data do not only show that the initial fall in GFR is
hemodynamic rather than structural, but also suggest that the
decline can, in fact, serve as an early marker of subsequent
slower decline of long-term renal function obtained from
RAAS inhibitor treatment. Evidence from large-scale placebo-
controlled trials to support this hypothesis is, however, lacking.
The Reduction in Endpoints in Non-Insulin-Dependent
Diabetes Mellitus with the Angiotensin-II Antagonist Losartan
or ig ina l a r t i c l e http://www.kidney-international.org
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(RENAAL) trial investigated the effects of the ARB losartan
versus placebo. The presence of a baseline period without
RAAS inhibitor treatment and the availability of serum
creatinine values on baseline and every 3 months during
therapy allows us to study the associations between treatment-
induced short-term responses in estimated GFR (eGFR) on
one hand and its long-term renal function decline on the
other.
RESULTS
Course of eGFR in losartan- and placebo-treated individuals
The eGFR course during the RENAAL trial is shown in
Figure 1. The fall in eGFR at 3 months after the start of
treatment was greater in losartan-treated individuals com-
pared with placebo (2.3 (95% confidence interval (CI)
2.7–1.8) vs 1.6 (2.0–1.1) ml/min per 1.73 m2, respectively,
P¼ 0.031). The initial fall in eGFR was inversely associated
with the long-term eGFR slope, such that the long-term
eGFR slope in the losartan group was significantly smaller
compared with placebo (4.2 (95% CI 3.9 to 4.6) vs 5.0
(4.7 to 5.4) ml/min per 1.73 m2 per year; Po0.001,
respectively).
Predictors of an acute fall in eGFR
The initial change in eGFR in the losartan group showed a
wide variability: mean 2.3 ml/min per 1.73 m2 (min 18.3;
max þ 14.7). In univariate analysis, urinary albumin/creatinine
ratio (UACR) and the month 3 change in UACR showed the
strongest associations with the degree of the initial eGFR fall
(Table 1). In multivariable analysis, male gender, a higher
baseline eGFR, UACR, and diastolic blood pressure, a lower
hemoglobin, and a larger month 3 decline in UACR were stati-
stically significantly associated with a larger acute fall in eGFR.
Effect of acute fall in eGFR on long-term renal function
decline
To assess whether a more pronounced acute fall in eGFR
during losartan therapy was associated with a more stable
long-term eGFR course, patients assigned to losartan were
stratified in tertiles according to the initial change in eGFR.
The baseline characteristics of the losartan participants
with available baseline and month 3 eGFR values are shown
in Table 2. Patients with a larger acute fall in eGFR had a
significantly higher UACR, eGFR, and systolic blood pressure
at baseline and had greater reduction in UACR and systolic
blood pressure after 3 months compared with those with a
moderate fall or rise in eGFR.
In participants allocated to losartan, the mean eGFR at
the median time (month 33) was lower in patients with an
initial decline compared with those with an initial rise in
eGFR (28.7 (95% CI 26.3–31.0) vs 33.0 (30.9–35.2 ml/min per
1.73 m2; P¼ 0.007; Figure 2). In addition, when the eGFR
slope was calculated from baseline, eGFR decline was higher
in subjects with an initial fall compared with those with an
initial rise in eGFR (5.2 (95% CI 5.8 to 4.7) vs 3.6
(4.1 to 3.0 ml/min per 1.73 m2 per year; Po0.001).
A different pattern emerged when the initial eGFR effect was
excluded and long-term eGFR decline was calculated from 3
months to the final visit. In unadjusted analyses, patients
with a large initial fall in eGFR showed a more stable long-
term eGFR course compared with patients with a moderate
fall or an increase in initial eGFR (3.8 (95% CI 4.4 to
3.2) vs 4.1 (4.7 to 3.6) vs 4.8 (5.4 to 4.3) ml/min
per 1.73 m2, respectively, P¼ 0.0094 for tertile 1 vs 3).
A multivariable analysis, adjusting for baseline characteristics
and response parameters, demonstrated that an initial steeper
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Figure 1 |Mean estimated glomerular filtration rate (eGFR)
levels through 39 months among patients who were assigned
to receive losartan and placebo. The data and slope shown in
the insert display the calculated eGFR data by linear mixed effects
model. The long-term eGFR slopes in the losartan and placebo
group are calculated from month 3 in the current analysis. The
long-term eGFR decline originally reported by Brenner et al.1 was
calculated from baseline, which explains the slight differences
between the original publication and the current report.
Table 1 | Independent predictors of initial eGFR change in
losartan group calculated in univariable and multivariable
regression model
Regression coefficient P-value
Univariable adjustment
UACR 1.157 o0.001
Systolic BP 0.040 0.002
Hemoglobin 0.333 0.011
Total cholesterol 0.009 0.029
Month 3 change UACR 1.640 o0.001
Month 3 change systolic BP 0.057 o0.001
Month 3 change diastolic BP 0.103 o0.001
Multivariable adjustmenta
UACR 0.213 0.001
Hemoglobin 0.199 0.012
Month 3 change UACR 0.169 o0.001
Gender 0.086 0.036
eGFR 0.155 o0.001
Diastolic BP 0.085 0.034
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; UACR,
urinary albumin/creatinine ratio.
aCovariates are shown with a significant contribution to the multivariable model.
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fall in eGFR remained statistically significantly associated
with a more stable long-term eGFR course (Figure 3). This
correlation between the initial eGFR fall and long-term eGFR
decline was exclusively observed in losartan-treated patients.
No correlation was observed between the acute fall in eGFR
and long-term eGFR decline in placebo-treated subjects nor
was there any association between an acute fall in eGFR
and long-term eGFR slope other than defined by a fall from
baseline to month 3. The results of a sensitivity analysis
using serum creatinine instead of eGFR were similar to the
primary analysis.
Instead of looking at eGFR changes over time, we
could also analyze the data on hard outcomes (doubling of
serum creatinine or ESRD). When the overall population was
divided in tertiles, the rate of renal events was higher in those
with an initial fall compared with those with an initial rise
in eGFR. However, in patients with an initial fall in eGFR, the
rate of renal events was profoundly attenuated in losartan-
treated patients compared with placebo. In contrast, in those
with an initial rise in eGFR, renal event rate was almost
similar between both treatment groups (Table 3).
DISCUSSION
In this study we demonstrated that initiation of antihyper-
tensive therapy with an ARB induces an acute fall in eGFR
that is inversely correlated with renal function decline during
long-term follow-up. Specifically, the greater the acute eGFR
fall, the slower the rate of long-term eGFR decline. This
relationship is independent of other risk markers or changes
in risk markers for progression of renal disease such as blood
pressure and albuminuria.
Table 2 | Baseline characteristics of losartan-assigned patients by tertiles of initial change in eGFR
Variable
Tertiles of initial change in eGFR
tertiles 1 2 3
D eGFR (ml/min per 1.73m2) 8.6 (4.0) 2.4 (1.3) +4.2 (4.9)
N 239 240 240
Age (years) 59.1 (7.5) 60.3 (7.5) 60.6 (7.0)
Gender (% male) 154 (64.4) 140 (58.3) 146 (60.8)
eGFR (ml/min per 1.73m2) 41.1 (12) 38.0 (13) 39.7 (11)
Systolic BP (mmHg) 153.6 (20) 152.6 (19) 149.2 (17)
Diastolic BP (mmHg) 82.7 (11) 82.5 (9.7) 81.8 (10.8)
Serum creatinine (mg/dl) 1.8 (0.5) 1.9 (0.5) 1.8 (0.5)
UACR (mg/g) (median; IQR) 1525 (587–3417) 1359 (627–2900) 893 (480–1692)
Hemoglobin (mg/dl) 12.4 (1.9) 12.4 (1.8) 12.7 (1.8)
Total cholesterol (mg/dl) 232.3 (62) 226.4 (49) 221.8 (53)
HbA1c (%) 8.4 (1.6) 8.6 (1.6) 8.5 (1.7)
Diuretic (n, %)a 142 (59.4) 144 (60.0) 137 (57.1)
b-Blocker (n, %)a 51 (21.3) 44 (18.3) 41 (17.1)
Calcium antagonist (n, %)a 172 (72.0) 178 (74.2) 164 (68.3)
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; UACR, urinary albumin/creatinine ratio.
aThere were no marked differences in other blood pressure-lowering therapies between losartan-treated subjects during long-term follow-up.
Values are expressed as mean with s.d. UACR and change in UACR is expressed as median with interquartile range (IQR).
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Figure 2 |Mean estimated glomerular filtration rate (eGFR)
levels through 39 months in patients assigned to losartan
therapy with a decline (8.6±4.0ml/min per 1.73m2) or rise
in eGFR (þ 4.2±4.9ml/min per 1.73m2) from baseline to
month 3.
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Figure 3 | Long-term estimated glomerular filtration rate
(eGFR) slope stratified by acute fall in eGFR in losartan-
assigned patients. Adjustment for covariates in the multivariable
mixed effects model included gender, eGFR, diastolic blood
pressure, hemoglobin, urinary albumin/creatinine ratio (UACR)
and month 3 change in UACR. The numbers in each bar reflect the
annual mean long-term eGFR slope.
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The pharmacological effects of RAAS blockers on the
GFR course can be best explained by a two-slope model of an
acute fall in GFR up to 3 months and an attenuation of the
long-term GFR slope until end of treatment. The acute fall in
GFR could be of structural origin, because of a treatment-
induced reduction in the number of functioning nephrons,
or of hemodynamic origin. If the acute GFR fall induced
by RAAS blockade is a hemodynamic response, treatment
withdrawal should lead to an increase in GFR in the same
order of magnitude as the initial fall. Indeed, a couple of
studies demonstrated that after withdrawal of antihyperten-
sive therapy, the GFR increased in the majority of patients
and correlated with the initial GFR fall.9,10 These data
support the notion that the initial fall in GFR during RAAS
blockade is of hemodynamic and not of structural origin.
The opposite hemodynamic and structural effects on GFR
provide an ambiguous picture of the relationship between
angiotensin receptor blockade and the rate of renal function
decline. The acute reversible hemodynamic effect creates a
pattern in which the long-term slope starting several months
after randomization differs from the mean slope determined
from baseline to study end. Indeed, we observed that within
losartan-treated subjects, the long-term renal function slope
determined from month 3 differed from the slope assessed
from baseline to month 39. It should be remembered that the
aim of renoprotective therapies is to delay or prevent changes
in renal structural function. Therefore, renoprotective
therapies focus on attenuating the long-term structural renal
function decline, excluding the early hemodynamic effect. In
this respect, losartan-treated subjects with a larger fall in
eGFR during the first 3 months had indeed a subsequent
slower rate of long-term renal function decline. However,
when the eGFR slope was calculated from baseline, eGFR
decline was significantly higher in patients with an initial fall
compared with those with an initial rise in eGFR. This may
be attributed to the large initial hemodynamic effect that may
have negated the long-term beneficial effect and obscured the
effect on structural renal function. It is tempting to speculate
that after a longer follow-up, this becomes apparent in a
crossing of the long-term slopes as we also observed for the
losartan–placebo comparison. However, the relatively short
follow-up period precludes the verification of this possibility.
Because of the opposite reversible hemodynamic effects that
many drugs and dietary interventions exert, we recommend
that clinical trials using GFR-based slopes as outcome should
report the slope of (long-term) renal function decline starting
several months after randomization and verify the reversi-
bility of the initial (hemodynamic) effect by determining
eGFR several months after treatment discontinuation.
Similar opposite short-term and long-term effects of
different interventions on GFR decline have been observed in
past clinical trials. In the Modification of Diet in Renal
Disease (MDRD) study, non-diabetic patients assigned to a
low-protein diet had a faster mean decline in GFR during the
first 4 months but a slower mean GFR decline thereafter.
Because the opposite directions of a low-protein diet on GFR
balanced each other, the primary comparison of the MDRD
study was judged to be inconclusive.11,12 Apperloo et al.9
showed in non-diabetic renal patients that patients treated
with an ACE inhibitor showed an acute initial fall in GFR.
Again this fall was highly variable among the different
patients. Those patients with a greater initial fall in GFR had
a significant less steep GFR slope during long-term follow-
up.9 A systematic review of 12 randomized (small) clinical
trials demonstrated that the acute fall in eGFR or rise in
serum creatinine was inversely related with the subsequent
rate of renal function decline.8 The finding of our study
substantiates the inverse correlation between the acute fall
and chronic eGFR slope in losartan-treated patients. This
study is thus the first large study in diabetes demonstrating
the inverse association between initial GFR changes and long-
term renal function decline.
The principle analyses were based on eGFR decline over
time and not on the available hard renal end points like
doubling of serum creatinine or ESRD. Selecting patients
based on the initial change in serum creatinine (eGFR)
directly influences the doubling of serum creatinine end
point. It is therefore of no surprise that if we select those with
an initial rise in serum creatinine (fall in eGFR), the renal
event rate (doubling of serum creatinine or ESRD) is higher
compared with patients with an initial fall in serum
creatinine (rise in eGFR). However, if we take this into
account and look at the group that has an initial fall in eGFR,
we do see that the renal protective effect of losartan
compared with placebo is much higher than in the patients
who had a rise in eGFR. This indicates that a fall in eGFR on
losartan is less worse than on placebo with respect to hard
renal outcomes as well.
Table 3 | Renal events (doubling of serum creatinine or ESRD) according to tertiles of initial change in eGFR in losartan- and
placebo-allocated patients
Losartan Placebo
Mean (s.d.) initial eGFR
change (ml/min per 1.73m2)a Events (%)
Event rate
(per 100 patient year)a Events (%)
Event rate
(per 100 patient years)a
8.3 (2.7) 98 (39.2) 15.6 113 (49.6) 21.6
2.1 (1.3) 73 (29.7) 10.8 86 (36.9) 13.8
+4.6 (4.8) 46 (20.6) 6.9 54 (21.2) 7.3
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, end-stage kidney disease.
aThe mean initial eGFR changes in each tertile differ from those presented in Table 2 as the tertiles of initial eGFR change presented in Table 3 were created in the overall
population (losartan and placebo groups).
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What could be the mechanism for this hemodynamic
acute fall in GFR and its relationship with long-term GFR
decline? First of all, it could be possible that these effects are
caused by a regression to the mean phenomenon. However,
the fact that no correlation was observed between the acute
fall in eGFR and long-term eGFR decline in the placebo
group and the fact that no correlation was observed when
the initial change in eGFR was calculated from baseline to
month 6 or month 9 in losartan-assigned patients make this
assumption less likely. A physiological explanation is that in
the presence of diabetes and hypertension, a dysfunction of
the autoregulation of the afferent renal arteriole leads to
increased transmission of the systemic blood pressure into
the glomerular capillary network.13 This results in increased
intraglomerular pressure and flow and eventually contributes
to glomerular sclerosis and proteinuria.14,15 Evidence that
increased glomerular pressure and flow initiate this injury
comes from animal studies demonstrating that reversing
these hemodynamic processes, by means of ACE inhibitor
treatment or low-protein diet, confer protection against
structural damages.16,17 In other words, control of intraglo-
merular pressure, even in the presence of continued systemic
hypertension, contribute to the long-term stability of kidney
function. RAAS blockade causes efferent renal vasodilation
that in turn causes a reduction in intraglomerular pressure, a
reduction in filtration fraction, and an acute fall in GFR.
Thus, the reduction in intraglomerular pressure may be the
link between RAAS blockade-induced acute reductions in
GFR and the ability of this therapeutic strategy to delay long-
term renal function decline. Furthermore, the variability in
response may be reflection of the difference in intraglomer-
ular pressure and/or the difference in the drug effect.
Some limitations need to be addressed when interpreting our
findings. This is a post hoc analysis of a large randomized
controlled trial. Analyses according to the change in eGFR are
no longer randomized; thus, although we adjusted for a range of
clinical characteristics between groups, residual confoun-
ding cannot be excluded. The results can therefore only be
interpreted as hypothesis generating. Second, no data on
eGFR slope are available in individual patients before enroll-
ment in the RENAAL trial. Therefore, we are not able to verify
that patients with an acute eGFR fall had a less steep slope
before initiation of therapy. We were therefore not able to
distinguish between patients who respond to therapy compared
with those who have progressive renal function loss.It must
therefore be emphasized that a fall in eGFR can be the result of
treatment or progressive renal function loss. One should
therefore always interpret the eGFR fall in the context of other
clinical conditions. Finally, we used the MDRD formula to
calculate eGFR. It is known that such estimations suffer from
both bias and imprecision.18 Because of this imprecision,
our results likely convey an underestimation of the strength of
the association between the acute fall in GFR and its correlation
with long-term renal function decline.
This study has several clinical implications. First, our data
suggest that a fall in eGFR after start of RAAS inhibitor may
be an indicator of the responsiveness to therapy instead of a
safety issue, in particular in the context when albuminuria
and blood pressure are reduced as well. This can be
interpreted as an encouragement to continue treatment, as
long as other causes contributing to the fall in eGFR, such as
renal artery stenosis or diminished arterial blood volume or
safety issues such as hyperkalemia, can be excluded.8 Second,
our data have important consequences for the design and
interpretation of clinical trials investigating the effects of
drugs on GFR course. Calculation of the eGFR slope during
antihypertensive treatment is based on the assumption
that the slope is constant during follow-up. Our results,
demonstrating a two-slope model of an acute hemodynamic
eGFR response and a long-term eGFR decline, show that this
assumption does not hold true. This highlights our
recommendation to analyze and report the initial and long-
term eGFR decline separately when determining the effects of
antihypertensive agents on renal function. However, reports
on the effects of antihypertensive agents on renal function
still analyze and report the GFR from baseline to end of
study.19,20 Interpretation of changes in renal function in such
reports is then based on both the hemodynamic and
structural effects of the agent and provide a misleading
picture of the effect of the antihypertensive agent on
structural renal function.
In conclusion, an initial fall in eGFR during ARB
treatment is independently inversely associated with less
renal function loss during continued treatment. These
opposite effects warrant caution in interpreting the results
of clinical trials using slope outcomes defined by GFR. We
recommend separate reporting of the drug-induced short-
term and long-term effect on GFR.
MATERIALS AND METHODS
RENAAL study design
The RENAAL study was a double-blind, randomized, placebo-
controlled trial that was designed to evaluate the renoprotective
effects of a losartan-based antihypertensive regimen compared with
a traditional blood pressure-lowering regimen in patients with type
2 diabetes, hypertension, and nephropathy. The study design,
inclusion and exclusion criteria, and results have been reported
elsewhere.1,21 In brief, participants were considered to have type 2
diabetes if they were 430 years old at the time of diagnosis of
diabetes, had no history of ketoacidosis, and did not use insulin
therapy within 6 month after diagnosis. A serum creatinine between
1.3 and 3.0 mg/dl (1.5–3.0 mg/dl for males 460 kg), UACR from a
first morning specimen of at least 300 mg/g, HbA1co12%, and age
between 31 and 70 years were part of the inclusion criteria. After a
6-week screening phase, patients were randomly assigned to either
losartan 50 mg (titrated to 100 mg after 4 weeks) or placebo.
Additional antihypertensive medications (calcium channel blockers,
b-blockers, centrally acting agents, and diuretics, excluding ACE
inhibitors or other ARBs) were permitted during follow-up to reach
the blood pressure goal of o140/90 mm Hg (systolic/diastolic).
The mean follow-up duration was 3.4 year with a range of 2.3 to 4.6
years. The RENAAL trial was conducted according to the Dec-
laration of Helsinki Principles. All patients signed informed consent.
The protocol was approved by all relevant ethics committees.
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Study visits, measurements, and outcomes
Participants were seen at a screening visit, randomization visit, at
1 and 3 months after randomization, and subsequently at 3 months
intervals. At each visit, serum creatinine and electrolytes were
measured. The MDRD equation was used to estimate GFR.22 The
dose of losartan was titrated toward the maximum recommended
dose of 100 mg at the first month visit. The acute change in eGFR
was assessed from baseline to month 3, 2 months after institution
of the maximum recommended dose of losartan.21 Renal events
were defined as a confirmed doubling in serum creatinine from
baseline or ESRD, which was defined as chronic dialysis or renal
transplantation. All end points were adjudicated by an independent
outcome committee.
Statistical analyses
The difference in short-term and long-term eGFR change between
placebo and losartan was calculated from baseline to month 3 and
from month 3 to month 39. The difference in long-term eGFR slope
between both treatment groups was estimated by a linear mixed
effects model with random intercepts and random slopes. As an
acute fall in eGFR was only observed in individuals assigned to
losartan, we investigated which factors predicted an initial fall in
eGFR during losartan therapy. A multivariable model was used for
this purpose. The following covariates were included in the model:
age, gender, body mass index, log-transformed UACR, systolic and
diastolic blood pressure, hemoglobin, total cholesterol, diuretic use
at baseline, and change from baseline to month 3 in log-transformed
UACR, and systolic and diastolic blood pressure. Baseline char-
acteristics that were statistically significantly associated with an acute
fall in eGFR were selected for the multivariable regression model.
Baseline characteristics not associated with eGFR decline in
univariate analyses were step-wise added to the multivariable model
to test their inclusion for statistical significance. Subsequently, we
questioned whether those individuals with a more pronounced
acute fall in eGFR showed a more stable course during long-term
follow-up. Therefore, we compared the long-term eGFR slope for
losartan-treated individuals within subgroups (tertiles) of acute fall
in eGFR. This approach was aimed at identifying subgroups with
identical number of patients to increase the power of the analysis
while minimizing the risk of bias. The long-term eGFR slope in each
tertile of acute fall in eGFR was estimated by a linear mixed effects
model with random intercepts and random slopes. To assess
whether the long-term slope correlated with the acute eGFR fall
independently of other patient characteristics or response para-
meters, the initial fall in eGFR was controlled for various covariates
including baseline eGFR, diastolic blood pressure, hemoglobin,
gender, log-transformed UACR, and month 3 change in log-
transformed UACR. In a sensitivity analysis eGFR was replaced for
serum creatinine. Means and s.d. are provided for continuous
variables, whereas number of patients and percentages are provided
for class variables. A two-sided P-value p0.05 was used to indicate
statistical significance. All analyses were conducted with SAS version
9.1 software (SAS Institute, Cary, NC).
DISCLOSURE
The RENAAL study was funded by Merck. BMB, MEC, DdZ, and H-HP
have received financial support from Merck for their participation in
the Steering Committee. All the other authors declared no competing
interests.
ACKNOWLEDGMENTS
We acknowledge the supportive role of all RENAAL investigators,
support staff, and participating patients.
REFERENCES
1. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal
and cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med 2001; 345: 861–869.
2. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the
angiotensin-receptor antagonist irbesartan in patients with nephro-
pathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
3. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of
irbesartan on the development of diabetic nephropathy in patients with
type 2 diabetes. N Engl J Med 2001; 345: 870–878.
4. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type
2 diabetes. N Engl J Med 2004; 351: 1941–1951.
5. Bjorck S, Mulec H, Johnsen SA et al. Renal protective effect of enalapril in
diabetic nephropathy. BMJ 1992; 304: 339–343.
6. Hillege HL, van Gilst WH, van Veldhuisen DJ et al. Accelerated decline and
prognostic impact of renal function after myocardial infarction and the
benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003;
24: 412–420.
7. Tarnow L, Rossing P, Jensen C et al. Long-term renoprotective effect of
nisoldipine and lisinopril in type 1 diabetic patients with diabetic
nephropathy. Diabetes Care 2000; 23: 1725–1730.
8. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated
elevations in serum creatinine: is this a cause for concern? Arch Intern Med
2000; 160: 685–693.
9. Apperloo AJ, de ZD, de Jong PE. A short-term antihypertensive
treatment-induced fall in glomerular filtration rate predicts long-term
stability of renal function. Kidney Int 1997; 51: 793–797.
10. Hansen HP, Rossing P, Tarnow L et al. Increased glomerular filtration rate
after withdrawal of long-term antihypertensive treatment in diabetic
nephropathy. Kidney Int 1995; 47: 1726–1731.
11. Levey AS, Adler S, Caggiula AW et al. Effect of dietary protein on the
progression of moderate renal disease in the Modification of Diet in Renal
Disease study. J Am Soc Nephrol 1996; 7: 2616–2626.
12. Levey AS, Green T, Beck GJ et al. Dietary protein restriction
and the progression of chronic renal disease: what have all
the results of the MDRD study shown? J Am Soc Nephrol 1999; 10:
2426–2439.
13. Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR
in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997;
52: 1369–1374.
14. Anderson S, Brenner BM. The role of intraglomerular pressure in the
initiation and progression of renal disease. J Hypertens Suppl 1986; 4:
S236–S238.
15. Anderson S, Brenner BM. Intraglomerular hypertension: implications
and drug treatment. Annu Rev Med 1988; 39: 243–253.
16. El-Nahas AM, Paraskevakou H, Zoob S et al. Effect of dietary
protein restriction on the development of renal failure after subtotal
nephrectomy in rats. Clin Sci (Lond) 1983; 65: 399–406.
17. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal
hypertension in the initiation and progression of diabetic and other
glomerulopathies. Am J Med 1982; 72: 375–380.
18. Freedberg DE. To eGFR or not to eGFR: here is an intern’s answer.
Kidney Int 2009; 76: 129–130.
19. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different
fixed-dose combination therapies in patients with hypertension at
high risk for cardiovascular events (ACCOMPLISH): a prespecified
secondary analysis of a randomised controlled trial. Lancet 2010;
375: 1173–1181.
20. Lambers Heerspink HJ, de Zeeuw D. Composite renal endpoints: was
ACCOMPLISH accomplished? Lancet 2010; 375: 1140–1142.
21. Brenner BM, Cooper ME, de Zeeuw D et al. The losartan renal protection
study–rationale, study design and baseline characteristics of RENAAL
(Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist
Losartan). J Renin Angiotensin Aldosterone Syst 2000; 1: 328–335.
22. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Modification of Diet in Renal Disease Study Group. Ann Intern
Med 1999; 130: 461–470.
Kidney International (2011) 80, 282–287 287
FA Holtkamp et al.: eGFR change during treatment with losartan o r ig ina l a r t i c l e
